VarCT Diagnostics established

We are very happy to today announce the foundation of VarCT Diagnostics ApS, a sister company to VAR2 Pharmaceuticals. VarCT Diagnostics will, based on our proprietary malaria protein, focus on the development of a universal tool to capture circulating tumour cells (CTC) as means for diagnosis, prog......
Continue reading

VAR2 Pharmaceuticals management team expands with experienced drug development COO

As of May 1st,  Dr. Andreas L Norlin has taken up the position as Chief Operating Officer. Andreas comes with a deep knowledge of drug development strategy and execution from more than 20 years in research, pre-clinical and clinical development in academia, biotech and big pharma, most recently......
Continue reading

First VAR2 patent issued

It is with great pleasure that VAR2 Pharmaceuticals can announce that our first patent has been issued by the Australian Government (IP Australia). Key claims on the use of recombinant VAR2CSA for targeting, treating and diagnosing cancer was accepted and issued.

Continue reading

Therapeutic access to cisplatin-resistant bladder cancer using VAR2-Drug Conjugates

Cisplatin is worldwide standard-of-care chemotherapy in muscle-invasive bladder cancer (MIBC). However, many patients develop resistance to cisplatin with no second-line treatment options currently available. A new study published on April 10, 2017 in European Urology demonstrates VAR2-mediated drug......
Continue reading